ReviewLife (Basel, Switzerland)2023
Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Automated insulin delivery in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis.Acta diabetologica · 2025Pooled it
- Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.Frontiers in endocrinology · 2025Trial
- Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care.Journal of diabetes science and technology · 2026Article
- Technology readiness associated with insulin pump and automated insulin delivery system use in young adults with type 1 diabetes.Journal of health psychology · 2026Article
- In-flight glycaemic control using automated insulin delivery systems: A within-subject comparative pilot study.Diabetes, obesity & metabolism · 2026Article
- Article
- Revolutionizing diabetes care: the role of artificial intelligence in prevention, diagnosis, and patient care.Journal of diabetes and metabolic disorders · 2025Review
- Factors Considered Important by Diabetes Providers Before Recommending Automated Insulin Delivery Systems: Observations From the T1D Exchange Quality Improvement Collaborative.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment.Frontiers in endocrinology · 2025Article
- Real-world efficacy of MiniMed™780G recommended settings (glycemic target 100 mg/dL, active insulin time 2 hours) in youth and young adults with type 1 diabetes.Frontiers in endocrinology · 2025Article
- Advances in diabetes technology within the digital diabetes ecosystem.Journal of managed care & specialty pharmacy · 2024Review
- Innovation is the driver behind quality improvements in diabetes care delivery.Journal of managed care & specialty pharmacy · 2024Article
- Reinforcement Learning: A Paradigm Shift in Personalized Blood Glucose Management for Diabetes.Biomedicines · 2024Article
- Advancements in Insulin Pumps: A Comprehensive Exploration of Insulin Pump Systems, Technologies, and Future Directions.Pharmaceutics · 2024Review
- Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study.Frontiers in endocrinology · 2024Article
- Advanced Hybrid Closed Loop users' satisfaction of telemedicine and telenursing in pediatric and young adult type 1 diabetes.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) patients' lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems' efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.